Explore
Trendline
ImmunityBio Faces Securities Fraud Class Action Over Misleading Anktiva Claims
ImmunityBio Faces Securities Fraud Class Action Over Misleading Anktiva Claims
Read More
Trendline
Rosen Law Firm Invites ImmunityBio Investors to Lead Securities Fraud Lawsuit
Rosen Law Firm Invites ImmunityBio Investors to Lead Securities Fraud Lawsuit
Read More
Trendline
Rosen Law Firm Investigates Disc Medicine Following FDA Rejection of Drug Application
Rosen Law Firm Investigates Disc Medicine Following FDA Rejection of Drug Application
Read More
Trendline
Kessler Topaz Meltzer Check Launches Investigation into Badger Meter's Financial Performance
Kessler Topaz Meltzer Check Launches Investigation into Badger Meter's Financial Performance
Read More
Trendline
Aldeyra Therapeutics Faces Securities Fraud Lawsuit Over Misleading Clinical Trial Results
Aldeyra Therapeutics Faces Securities Fraud Lawsuit Over Misleading Clinical Trial Results
Read More
Trendline
Faruqi Faruqi, LLP Alerts Super Micro Investors of Class Action Deadline Amid Legal Challenges
Faruqi Faruqi, LLP Alerts Super Micro Investors of Class Action Deadline Amid Legal Challenges
Read More
Trendline
Rosen Law Firm Urges SES AI Corporation Investors to Act Before Class Action Deadline
Rosen Law Firm Urges SES AI Corporation Investors to Act Before Class Action Deadline
Read More
Trendline
Rosen Law Firm Initiates Securities Fraud Lawsuit Against Vital Farms, Inc. Over ERP System Delays
Rosen Law Firm Initiates Securities Fraud Lawsuit Against Vital Farms, Inc. Over ERP System Delays
Read More
Trendline
Super Micro Faces Securities Class Action Amid DOJ Indictment
Super Micro Faces Securities Class Action Amid DOJ Indictment
Read More
Trendline
Rosen Law Firm Investigates Disc Medicine for Potential Securities Claims Following FDA Rejection
Rosen Law Firm Investigates Disc Medicine for Potential Securities Claims Following FDA Rejection
Read More
Trendline
Gemini Space Station Faces Securities Fraud Lawsuit Amid Stock Decline
Gemini Space Station Faces Securities Fraud Lawsuit Amid Stock Decline
Read More
Trendline
Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials
Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials
Read More